Valuation: OnKure Therapeutics, Inc.

Capitalization 158M 134M 123M 116M 216M 14.92B 218M 1.46B 568M 7.17B 593M 580M 24.74B P/E ratio 2026 *
-1.4x
P/E ratio 2027 * -1.79x
Enterprise value 158M 134M 123M 116M 216M 14.92B 218M 1.46B 568M 7.17B 593M 580M 24.74B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.03%
Yield 2026 *
-
Yield 2027 * -
1 day-1.26%
1 week-17.34%
Current month-25.81%
1 month-10.73%
3 months+56.40%
6 months+32.99%
Current year+34.83%
1 week 3.85
Extreme 3.85
5.04
1 month 3.85
Extreme 3.85
5.38
Current year 2.23
Extreme 2.23
5.38
1 year 1.7
Extreme 1.7
5.38
3 years 1.7
Extreme 1.7
20
5 years 1.7
Extreme 1.7
20
10 years 1.7
Extreme 1.7
20
Change 5d. change 1-year change 3-years change Capi.($)
-1.26%-17.34%+95.50% - 158M
-0.66%+0.79%-15.44%-16.46% 43.39B
-1.54%+6.21%+32.29%+22.92% 34.7B
-0.49%+1.67%+238.37%+480.24% 30.15B
+0.04%+13.27%+16.58%-5.85% 29.83B
-2.02%-1.05%+29.45%+33.41% 28.46B
-6.96%+0.55%+424.83%+4,203.98% 14.48B
-3.04%+8.03% - - 14.74B
-0.41%+0.57%+131.18%+115.21% 12.51B
-0.64%+0.54%+5.74%-8.68% 12.29B
Average -1.70%+1.32%+106.50%+603.09% 22.07B
Weighted average by Cap. -1.41%+3.64%+81.80%+376.77%

Financials

2026 *2027 *
Net sales - -
Net income -62.51M -53.11M -48.6M -45.87M -85.57M -5.9B -86.32M -577M -225M -2.84B -235M -230M -9.79B -68.57M -58.26M -53.32M -50.32M -93.87M -6.48B -94.7M -632M -247M -3.11B -257M -252M -10.74B
Net Debt - -
Logo OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Employees
45
Date Price Change Volume
26-05-08 3.910 $ -1.26% 89,568
26-05-07 3.960 $ -2.70% 93,835
26-05-06 4.070 $ -9.96% 185,115
26-05-05 4.520 $ -1.74% 95,207
26-05-04 4.600 $ -2.75% 113,282
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.910USD
Average target price
20.20USD
Spread / Average Target
+416.62%

Quarterly revenue - Rate of surprise